Are fondaparinux (Arixtra) injections preferable to warfarin (Coumadin) for management of anticoagulation in postoperative hip-fracture patients and those recovering from joint replacement surgery?

The CHMP’s green light for Arixtra (fondaparinux) was based on a review of two large-scale, pivotal Phase III trials involving more than 32,000 patients (OASIS 5 and 6), which demonstrated the drug’s ...

Arnhem, the Netherlands - The FDA has approved fondaparinux sodium (Arixtra® - Sanofi-Synthélabo/Organon) for the prophylaxis of deep vein thrombosis in patients undergoing hip fracture surgery, hip ...

To earn CME related to this news article, click here. January 21, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of the potential for ...

Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an ...

PHILADELPHIA, Oct. 2 (UPI) -- GlaxoSmithKline said Monday the U.S. Food and Drug Administration has granted priority review to Arixtra for acute coronary syndromes. The FDA's priority review means the ...

The FDA has asked for more information from GlaxoSmithKline regarding its application to use the anti-clotting drug Arixtra for unstable angina. GSK didn't elaborate on what the agency was looking for ...

> Acambis got the FDA's go-ahead on its smallpox vaccine, a key step in the company's quest for a long-term manufacturing contract with the U.S. government. The company says it's negotiating a deal ...

On the eve of its third-quarter results, shares of Europe's largest drug maker, GlaxoSmithKline , were up $1.02, or 1.8%, to $56.65 in New York after the company said its supplemental new drug ...